Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
JAMA
|
April 19, 2022
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply
Silje Watterdal Syversen, Jørgen Jahnsen, Espen A Haavardsholm
JAMA
|
September 21, 2021
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply
Silje Watterdal Syversen, Nils Bolstad, Espen A Haavardsholm
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 12, 2018
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis
Birgit M Wollmann, Silje Watterdal Syversen, Maria Vistnes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
October 31, 2022
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
RMD Open
|
December 16, 2021
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
Johanna Elin Gehin, Silje Watterdal Syversen, David John Warren, et al.
Arthritis Research & Therapy
|
December 1, 2019
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Johanna Elin Gehin, Guro Løvik Goll, David John Warren, et al.
Rheumatology (Oxford, England)
|
September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
RMD Open
|
November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Scandinavian Journal of Gastroenterology
|
August 23, 2022
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Kristin H Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
RMD Open
|
March 19, 2026
Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial
Teresa Holly, Marthe Kirkesaether Brun, Kristin Kaasen Jørgensen, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
JAMA
|
April 19, 2022
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply
Silje Watterdal Syversen, Jørgen Jahnsen, Espen A Haavardsholm
JAMA
|
September 21, 2021
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply
Silje Watterdal Syversen, Nils Bolstad, Espen A Haavardsholm
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 12, 2018
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis
Birgit M Wollmann, Silje Watterdal Syversen, Maria Vistnes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
October 31, 2022
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
RMD Open
|
December 16, 2021
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
Johanna Elin Gehin, Silje Watterdal Syversen, David John Warren, et al.
Arthritis Research & Therapy
|
December 1, 2019
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Johanna Elin Gehin, Guro Løvik Goll, David John Warren, et al.
Rheumatology (Oxford, England)
|
September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
RMD Open
|
November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Scandinavian Journal of Gastroenterology
|
August 23, 2022
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Kristin H Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
RMD Open
|
March 19, 2026
Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial
Teresa Holly, Marthe Kirkesaether Brun, Kristin Kaasen Jørgensen, et al.
Page
of 3